Coming Soon: Inside the Clinic Canine Lymphoma Treatment—Never a One Size Fits All

This CE will discuss how Laverdia CA-1 (verdinexor tabs) fit into treatment of dogs with lymphoma. We will discuss the mechanism of action, dosing, adverse events and efficacy of this novel agent. Finally discussing why Laverdia CA-1 should be utilized in the primary care setting.

1. Learning Objectives:

a) Understanding the class of drug

b) Understanding it’s mechanism of action

c) Understanding the data behind its conditional approval and how this impacts its current usage

d) Seeing where this drug is valuable in the primary care setting